Brandon Perez, MD
Obstetrics & Gynecology · Marrero, LANPI 1184890980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Aspira Women's Health Inc at 24.1% of the total. Reporting peaked in 2023 at $237 and has fallen 91.5% since, to $20 in 2025. That places this record below the midpoint for obstetrics & gynecology clinicians in LA, where the typical reported total is $1,022.
Across 27 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aspira Women's Health Inc$157
- AbbVie$102
- Hologic Sales And Service, LLC$77
- Astellas Pharma US Inc$60
- Pfizer$60
- Sumitomo Pharma America, Inc.$51
- plus $146 from 7 others
Across 205 payments — averaging $4328.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$578K
- Teva Pharmaceuticals USA, Inc.$144K
- Exeltis, USA Inc.$96K
- Myovant Sciences GmbH$39K
- Ventana Medical Systems, Inc.$30K
What the payments were for
- Food & beverage$653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aspira Women's Health Inc | 2 | $157 |
| AbbVie | 5 | $102 |
| Hologic Sales And Service, LLC | 3 | $77 |
| Astellas Pharma US Inc | 3 | $60 |
| Pfizer | 3 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Merck | 2 | $34 |
| Roche Diagnostics Corporation | 1 | $28 |
| Meditrina | 1 | $20 |
| Amgen | 1 | $17 |
| Millicent US Inc | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$653 in reported general payments places this provider in the 40th percentile of 608 obstetrics & gynecology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 39 | $2,647 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Marrero
- Rachel SpearsMarrero$9K
- Kim Anh TranMarrero$8K
- Eugenio LabadieMarrero$8K
- Veronica GillispieNew Orleans$117K
- Rachel Bezdekla Place$105K
- Earl PeeperNew Orleans$95K
- Thomas PayneBaton Rouge$84K
- Catherine VanderloosShreveport$55K
- George MorrisNew Orleans$34K
- Russell PhelpsLafayette$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.